|Year : 2022 | Volume
| Issue : 4 | Page : 320-326
Childhood steroid-resistant nephrotic syndrome: Long-term outcomes from a Tertiary Care Center
Shipra Agrwal1, Mukta Mantan2, Aashima Dabas2, Vineeta V Batra3
1 Department of Pediatrics, Army College of Medical Sciences, New Delhi, India
2 Department of Pediatrics, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India
3 Department of Pathology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, New Delhi, India
|Date of Submission||17-Jun-2021|
|Date of Acceptance||18-Sep-2021|
|Date of Web Publication||16-Jul-2022|
Department of Pediatrics, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi
Source of Support: None, Conflict of Interest: None
Introduction: Steroid-resistant nephrotic syndrome (SRNS) is a rare condition that accounts for about 10% to 20% of all nephrotic syndromes in children. While calcineurin inhibitors induce remission in the majority, the data on long-term outcomes are limited. This retrospective study aimed to look at the clinical profile, biopsy findings, and long-term treatment outcomes in children with SRNS. Methods: The records of all children (1–18 years) with SRNS with biopsy findings of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), or mesangioproliferative glomerulonephritis, who received treatment for a minimum period of 12 months and were in follow-up during the years 2007–2018 at a tertiary care teaching hospital were retrieved. The clinical, histopathological, and biochemical factors and treatment outcomes were recorded and analyzed. Results: Ninety-one (72 boys) children with a median (interquartile range [IQR]) age of onset of nephrotic syndrome as 48 (24–87) months were included. MCD and FSGS were the most common histopathological types (57.1% and 36.3%, respectively) and 62 (68.1%) patients had late steroid resistance. Calcineurin inhibitors (CNIs) were used in 86.8% of the children, and response rates with cyclosporine and tacrolimus for complete remission (CR) were 80% and 73.7%, respectively, with median (IQR) time to response being 3 (2–4) months. The presence of MCD on histology and the use of CNIs were significantly associated with CR (P < 0.01). At a median (IQR) follow-up of 5 (3–7) years, 76 (83.5%) children had either CR or partial remission, four (4.4%) developed chronic kidney disease and five (5.5%) died (three due to end-stage renal disease and two of infective complications). Conclusion: SRNS children with MCD on biopsy, late resistance, and response to CNIs have better long-term outcomes. Most patients respond to CNIs within the first 6 months of use and need therapy for at least 24 to 36 months.
Keywords: Calcineurin inhibitors, CKD, MCD, remission, SRNS, steroids
|How to cite this article:|
Agrwal S, Mantan M, Dabas A, Batra VV. Childhood steroid-resistant nephrotic syndrome: Long-term outcomes from a Tertiary Care Center. Indian J Nephrol 2022;32:320-6
|How to cite this URL:|
Agrwal S, Mantan M, Dabas A, Batra VV. Childhood steroid-resistant nephrotic syndrome: Long-term outcomes from a Tertiary Care Center. Indian J Nephrol [serial online] 2022 [cited 2022 Aug 19];32:320-6. Available from: https://www.indianjnephrol.org/text.asp?2022/32/4/320/351267
| Introduction|| |
Nephrotic syndrome is a chronic disorder in children characterized by edema, nephrotic range proteinuria, hypoalbuminemia, and hyperlipidemia. The annual incidence of the condition is 2–7 in 100,000 in children under 15 years of age with a prevalence of 16 in 100,000; the Asian population appears to have a higher prevalence., While most children respond to daily prednisolone therapy, failure to respond after 4 weeks of compliant steroid therapy indicates steroid-resistant nephrotic syndrome (SRNS) seen in about 10% to 20% of all children with the condition. There is variability in the prevalence of SRNS depending on the ethnicity with a prevalence of about 20% among European children to 27% to 54% among Asians.,
Patients with steroid-resistant disease pose the most difficult therapeutic challenge. These children are at risk for complications of unremitting nephrotic syndrome and developing end-stage kidney disease (ESKD) in the long term. Medications like cyclosporine, tacrolimus, intravenous cyclophosphamide, intravenous steroids, and most recently rituximab are used for inducing and maintaining remission in these patients; these drugs cause intense immunosuppression.
The largest data till date reported outcomes of SRNS from the PodoNet registry, which primarily had European children of Caucasian ancestry (90.3%). The same publication also showed 10-year ESKD-free survival rates of 43%, 94%, and 72% in children with nonresponse (NR), complete remission (CR), and partial remission (PR), respectively, with 79% and 52% in children with biopsy findings of minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS)., Non-responders are at high risk of developing chronic kidney disease (CKD) with a prevalence of up to 50%. While the information on long-term outcomes of SRNS is available for Caucasian and African American children, studies from India have looked mostly at the short-term outcomes after the administration of different immunosuppressive agents., Ethnicity appears to influence the outcomes, and as most children with SRNS receive calcineurin inhibitors (CNIs), the long-term outcome is also dependent on the response to these agents and their inherent nephrotoxicity., This retrospective study was done to determine the clinicopathological profile and long-term outcomes of Indian children with SRNS.
| Methods|| |
This study was done in the department of pediatrics of a tertiary care teaching hospital located in the northern part of India. The records of all children with SRNS (initial and late resistance) with biopsy findings of MCD, FSGS, or mesangioproliferative glomerulonephritis (MesPGN), who were treated and were in follow-up in pediatric nephrology clinic during the period 2007–2018 were retrieved. Patients with a minimum follow-up of 12 months and complete records were included for the study analysis; children with congenital and secondary nephrotic syndrome were excluded. The study protocol was approved by the institute's ethical committee.
A study pro forma was filled for each patient that included information related to demographics, onset of nephrotic syndrome, histopathological features, therapy details, and outcomes.
SRNS was defined as failure to respond to 4 weeks of compliant steroid therapy in the absence of any documented infection. Children who failed to respond in the first episode were termed as initial resistance, whereas late resistance was defined as failure to achieve remission after initial response to steroids. Standard definitions were used for defining steroid-dependent nephrotic syndrome (SDNS), frequently relapsing nephrotic syndrome (FRNS), and infrequently relapsing nephrotic syndrome (IFRNS).
Complete remission (CR) was defined as the presence of trace or negative dipstick proteinuria or spot urine protein to creatinine ratio less than 0.2 mg/mg on follow-up. Partial remission (PR) was defined as the presence of 1–2+ dipstick proteinuria or protein to creatinine ratio from 0.2 to 2 mg/mg, serum albumin >3.0 g/dL, and no edema. The persistence of 3–4+ proteinuria or protein to creatinine ratio >2, albumin less than 2.5 g/dL, or edema constituted nonresponse (NR).
Children with SRNS underwent renal biopsy and were treated with immunosuppressants other than steroids based on the biopsy findings. Children with MCD, FSGS, and MesPGN were treated with CNIs (cyclosporine or tacrolimus) along with alternate-day prednisolone in tapering doses. Cyclosporine was given in doses of 4–5 mg/kg/day as two divided doses while tacrolimus was given in doses ranging from 0.08 to 0.15 mg/kg/day as two divided doses. Most patients received concomitant alternate-day prednisolone (0.25–1 mg/kg) in tapering doses for at least the first 12 months of therapy and angiotensin-converting enzyme inhibitor (enalapril 0.2–0.5 mg/kg/day). Both CNIs were given for a period of 2 to 3 years; rarely longer in some patients dependent on these drugs. Nonresponse to CNI was defined as lack of CR or PR after 6 months of compliant therapy. Serum levels of CNI for all patients could not be done due to in-house nonavailability and financial constraints. However, levels were done sparingly for patients who did not respond or showed clinical features of toxicity. Repeat biopsy was done for patients requiring CNI for more than 3 years to look for features of toxicity. Intravenous cyclophosphamide in doses of 500 mg/m2 as an infusion was given every month for six such pulses in some patients who did not respond to 6 months of compliant CNIs therapy or showed toxicity (hypertension, significant gum hyperplasia, or hypertrichosis) or had contraindications to them (acute kidney injury or tubulointerstitial damage on biopsy >20%). Those who responded but remained FRNS or SDNS subsequently received second-line alternative agents that included mycophenolate (MMF), rituximab, or interchange of CNIs. The patients were followed up regularly every 3 months with kidney function tests, serum albumin, and cholesterol and evaluated for clinical and biochemical response and side effects. Genetic testing could not be performed in any child due to financial constraints.
Demographic data such as the age of onset and presentation, gender, type of resistance, biopsy findings, treatment received, and response to therapy were recorded. In case of late resistance, the prior disease type such as FRNS or SDNS was noted. Complications such as the presence of cushingoid habitus, gum hyperplasia, hypertrichosis, hypertension, infections (numbers, site), cataract, glaucoma, diabetes, and anthropometric parameters were recorded. The final long-term outcome was recorded as a steroid-sensitive nephrotic syndrome (IFRNS/FRNS/SDNS) or persistence of resistance (PR/NR), progression to CKD, or death.
The collected data were transformed into variables, coded, and entered into Microsoft Excel. The data were analyzed and statistically evaluated using SPSS (Statistical Package for the Social Sciences) Version 21 (IBM SPSS Statistics, Version 21.0. Armonk, NY, IBM Corp.). Quantitative data were expressed as mean and standard deviation, and median and interquartile range (IQR); the difference between two comparable groups with quantitative variables was tested by Student's t-test (unpaired) or Mann–Whitney U test. Qualitative data were expressed as proportions and compared with the Chi-square test or Fisher's exact test. A binary logistic regression model was used to assess factors predicting CR with clinical parameters and renal biopsy as independent variables. A P value less than 0.05 was considered statistically significant. Kaplan–Meier (KM) survival curves were drawn for the long-term outcomes.
| Results|| |
During the study period of 12 years, 135 children were treated as SRNS; 91 (72 boys) were finally included in the study after excluding two children with congenital nephrotic syndrome, 18 with secondary nephrotic syndrome, and 24 with nonavailability of complete data. The median (IQR) age at the onset of illness was 48 (24–87) months. While 31.9% had initial resistance, the remaining (68.1%) developed resistance after the initial response (late resistance) after a median (IQR) period of 12 (6.5–33) months. None of the patients had any family history of nephrotic syndrome. The demographic and clinical features of the study population are provided in [Table 1].
Response to immunosuppression
Sixty (65.9%) patients received cyclosporine and 19 (20.9%) received tacrolimus as the first-line therapy for SRNS, and CR was achieved in 48/60 (80%) and 14/19 (73.7%), respectively, within a median (IQR) duration of 3 (2–4) months. Twelve (13.2%) patients received cyclophosphamide due to contraindication to CNI, adverse reaction or nonresponse to CNI, and only one of them achieved CR. At the end of 1 year, CR was achieved in 63 (69.2%) patients and PR in nine (9.9%), while 19 (20.9%) remained nonresponsive to any therapy; the median (IQR) duration of CNI treatment was 2 (1.5–3) years.
Eighty-three patients had a follow-up of more than 2 years, and 66 (79.5%) of them were in CR, nine (10.8%) had PR, and eight (6.8%) had NR. Of those who achieved CR, 46/63 (73%) subsequently had IFRNS, whereas 14 (22.2%) had FRNS and three (4.8%) had SDNS. Forty-seven patients had a follow-up of more than 5 years and 27 (57.4%) were in CR, while four (8.5%) and 16 (37%) had PR and NR, respectively.
Final Outcome: After a median (IQR) follow-up of 5 (3–7) years, 63 (69.2%) of the patients had become infrequently relapsing, nine (9.9%) remained FRNS whereas four (4.4%) were SDNS; overall 83.5% patients had a favorable course. Seven (7.7%) children had a partial response to the therapy, whereas eight (8.8%) children remained nonresponsive, and of them, four developed CKD; five (5.5%) children died (three with ESKD and two with sepsis). There was an improvement in the height standard deviation score (SDS) from −1.65 at initial presentation to −1.3 at the last follow-up, whereas the weight SDS declined from −0.6 to −0.9.
About 46 (50.5%) patients required modification of immunosuppressive therapy during the follow-up period. The indications for use of MMF, rituximab, or another CNI were primarily NR in 19 (31.9%), PR in nine (12.7%), and FRNS or SDNS course after becoming steroid sensitive in 17 (27.6%) and CNI toxicity in one child. A comparison of clinical and biopsy features in children with CR or PR with NR is provided in [Table 2]. Use of CNIs was significantly associated with CR/PR (P < 0.0001). Biopsy findings were not significantly different between CR/PR and NR (P = 0.33), but when compared between CR and non-CR (PR/NR), MCD on biopsy was significantly associated with CR (P = 0.001). Also, the age of onset was significantly higher in the CR/PR group compared with the NR group. There was no significant association of gender and type of resistance with the remission rate. There was no significant difference in the response rates of cyclosporine and tacrolimus (odds ratio [OR]; 95% confidence interval [CI] = 0.34; 0.08–1.4; P = 0.14). A regression analysis with CR as the dependent variable showed the R2 value as 0.298 and the biopsy findings of MCD and use of CNI predicted CR significantly unlike other factors [Table 3]. KM analysis was performed for survival times of CR (event) for the groups based on initial or late resistance and use of CNI or alternative agents. The mean survival time was compared using log-rank test. [Figure 1] shows the KM curve for the type of resistance where the mean (95% CI) time period for CR with initial resistance was 6.43 (5.42, 7.43) and 6.61 (4.75, 8.47) years for late resistance; P = 0.76. The survival curves showed much better chances of CR in patients receiving CNI as first-line agents compared with those receiving other alternative agents [Figure 2], the mean (95% CI) time period for CR being 12.08 (9.02, 15.15) years for CNI and 5.79 (4.95, 6.63) years with other agents; P < 0.001.
|Figure 1: Kaplan–Meier survival curve showing the chances of complete remission (CR) in follow-up (in years) in patients with initial resistance (IR) and late resistance (LR)|
Click here to view
|Figure 2: Kaplan–Meier survival curve showing the chances of complete remission (CR) in follow-up (in years) in patients having received calcineurin inhibitors or other agents|
Click here to view
|Table 3: Logistic regression for the predictors of complete remission (n=91)|
Click here to view
Side effects of therapy
Side effects of therapy observed were hypertension in 22.7% (Stage 1 in 80% and Stage 2 in 20%), hypertrichosis (40%), and cushingoid habitus (34.1%); 31% developed significant gum hypertrophy. These children were normotensive to begin with but developed hypertension during the course of therapy. None of them had any features of end-organ damage (eye evaluation and echocardiography done for them). One child developed diabetes mellitus on tacrolimus and was subsequently shifted to cyclosporine, achieved CR, and the insulin requirement ceased in 3 months. Five (5.5%) patients developed cataracts and two needed surgery for it and another two (2.2%) developed glaucoma. Repeat biopsy was done in seven patients who received CNI for more than 3 years and four (57.1%) of them had features of chronic CNI nephrotoxicity. The incidence of infections and hypertension were similar in both cyclosporine and tacrolimus groups (P = 0.33 and 0.47, respectively).
Fifty-one episodes of infections were documented in 29 (31.9%) patients; 37 episodes of peritonitis occurred in 27 (29.7%) patients, eight (8.8%) patients had tuberculosis, four (4.4%) had pneumonia, and two had cellulitis during treatment and last follow-up. Only two (2.2%) children developed venous thrombosis during this period.
| Discussion|| |
While various studies have reported the response rates with the use of CNI in children with SRNS, the information on long-term outcomes from India is lacking.,, Most guidelines recommend treatment of SRNS with CNIs for a duration lasting 2 to 3 years., Treatment often changes the disease course, and the long-term renal outcomes are dependent on the achievement of prolonged remission and appearance of drug toxicity with prolonged use of CNIs. Ethnicity and genetics of SRNS too influence the long-term outcomes.,
The median (Q1, Q3) age of onset of nephrotic syndrome in our study was 48 (24, 87) months and 79.1% were boys; earlier studies too have shown similar results., Most (68.1%) patients had late resistance and developed resistance after a median (Q1, Q3) period of 12 (6.5, 33) months; other studies have shown a higher proportion of initial resistance, and time to develop late resistance has not been described previously., Underlying histopathology usually affects the clinical presentation and also the outcomes of children with SRNS; a higher proportion of MCD (57.1%) compared with 36.3% FSGS could have contributed to a lower prevalence of initial resistance in this study. Srivastava et al. reported the incidence of MCD and FSGS as 52.7% and 23%, respectively, in a cohort of children biopsied between 1984 and 1995. Later, Banaszak et al. compared the histopathology of childhood nephrotic syndrome over two consecutive decades (1985–1995 and 1996–2005) and reported a tendency toward increasing proportional incidence of FSGS and fall in the incidence of MCD. They also reported a simultaneous significant increase in steroid resistance, which they attributed partially to the rising incidence of FSGS. In 2005, an Indian study reported FSGS to be the most common histopathological finding in children with SRNS accounting for 59% of the total cases. A higher incidence of FSGS was further reported in later studies. A randomized controlled trial (RCT) from India reported the incidence of FSGS and MCD as 69% and 31%, respectively. A higher incidence of FSGS was also reported by the PodoNet registry (primarily European countries) data that looked at SRNS in children (n = 1,368) and documented a higher proportion of FSGS (56%) compared with MCD (21.1%). Almost 50.9% of children in their cohort had an onset of nephrotic syndrome between 1 and 5 years of age. The lower incidence of FSGS in our study could be due to the lower median age of the study population and were similar to one by Inaba et al., where the median age of onset was 3.2 years and also due to a higher proportion of late resistance. Besides the difference in the histopathology in our study may also be attributable to genetic and ethnic factors.
Overall, 69.2% of patients attained CR with CNIs within a median period of 3 months in our patient cohort. Children who achieved CR/PR were older than the children who did not achieve any response. This finding is in contrast with Trautmann et al., who did not find any significant difference in the age of onset of the children achieving CR, PR, or NR. Inaba et al. also showed that higher age of onset of SRNS (>11 years) was an independent risk factor for progression to ESKD. Genetic diagnoses were identified in 23.6% of the children with SRNS in the PodoNet registry, and chances of detecting a genetic etiology reduced with increasing age (35.6% in children 3–12 months of age compared with 15.6% in children 6–11 years of age). Only 10.4% of these children responded to immunosuppressive therapy. It is possible that in our study, some of the children with NR had underlying genetic etiology, although this could not be ascertained. RCTs and cohort studies show that therapy with cyclosporine or tacrolimus results in CR in 30% to 40% and CR or PR in 60% to 80% of patients., A higher proportion of CR in our study population could be due to a larger number of children having late resistance and MCD on biopsy. Other studies too have shown better response in patients with MCD.,
Attaining PR is an important predictor for a good outcome in children with SRNS; the risk of ESKD decreases by 85% to 90% if CR was achieved and by 50% for those with PR. Ten-year renal survival rates were 94% and 72%, respectively, for those with CR and PR, and only 43% for those with NR to immunosuppression in one cohort. After a median follow-up of 5 years, 83.5% of our patients had a favorable course (69.2% had IFRNS and 14.3% had FRNS/SDNS); four (4.4%) developed CKD, and the mortality was 5.5%, which was contributed by ESKD and complications of SRNS course. The better outcomes observed in the present study appear to be due to a higher proportion of late resistance, MCD on biopsy, and the treatment with CNIs as first line in 86.8% of children. The PodoNet registry reported 33% CR and 22.5% PR after a median follow-up of 3.7 years among SRNS children, and 78.5% of patients had received CNI.
Similar efficacy of cyclosporine and tacrolimus in inducing remission was observed in the present study (median time 3 months) consistent with the findings of a previous study. Büscher et al. also reported a good response with cyclosporine in nongenetic forms of SRNS (78% by 2.5 months), whereas the response was poor in the genetic form of SRNS (CR only in 3%). The side effects observed during therapy were comparable between the two CNIs although the incidence of hypertrichosis in 40% was exclusively among children on cyclosporine. Repeat biopsies for CNI toxicity were done in seven patients who required CNI for more than 3 years, and four (57.1%) of them showed features of CNI toxicity; a previous study on Indian children showed toxicity in 25% of biopsies after a median (Q1, Q3) duration of 30 (26, 35) months. The difference may be due to the very small number of biopsies performed in our study. Cyclophosphamide was used less commonly and accounted for only 12% of the immunosuppressive regimen; response rates were low (8.3%) consistent with the earlier report of >80% failure rate with these regimens.
The infection rates observed over a 5-year period were about 10 per year, and 72.5% of infections were spontaneous bacterial peritonitis, and 4.4% of children were treated for tuberculosis during the follow-up period. Also, the incidence of venous thrombosis was 2.2%. A previous RCT on comparison of tacrolimus and intravenous cyclophosphamide too observed a higher number (45%) of peritonitis episodes over a 12-month observation period. An incidence of 3.8% for thrombosis has been described in children with SRNS from Bulgaria.
A major limitation of the present study is its retrospective nature, and a significant number of patients had to be excluded due to incomplete records. Also, we were not able to do the genetics for patients with initial resistance (31.9%) due to nonavailability and financial constraints, although none of the patients had any family history of nephrotic syndrome or other renal diseases. However, considering the fact that SRNS is a rare disease in childhood and patient attrition is expected in long-term follow-up and this being a single-center study, these limitations are not completely unavoidable.
| Conclusions|| |
Based on the results of this study, we conclude that Indian children with SRNS, especially those with late resistance and MCD on biopsy, are more likely to respond to CNIs and have good long-term outcomes. There appears to be a higher occurrence of late resistance and MCD in this part of the world and with the early use of CNIs, the chances of complications decrease, and the overall growth parameters too improve.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Bakkali L, Pereira RR, Kuik D, Ket JCR, Wijk J. Nephrotic syndrome in The Netherlands: A population based cohort study and a review of the literature. Pediatr Nephrol 2011;26:1241-6.
Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet 2018;392:61-74.
Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health 2018;2:880-90.
Chanchlani R, Parekh RS. Ethnic differences in childhood nephrotic syndrome. Front Pediatr 2016;4:39.
Andreoli SP. Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children. Adv Ren Replace Ther 2004;11:105-9.
Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, Bodria M, Ozaltin F, Emma F, et al
. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 2017;28:3055-65.
Trautmann A, Bodria M, Ozaltin F, Gheisari A, Melk A, Azocar M, et al
. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: The PodoNet registry cohort. Clin J Am Soc Nephrol 2015;10:592-600.
Ali EMA, Makki HFK, Abdelraheem MB, Makke SO, Allidir RA. Childhood idiopathic steroid-resistant nephrotic syndrome at a single center in Khartoum. Saudi J Kidney Dis Transpl 2017;28:851–9.
Prasad N, Manjunath R, Rangaswamy D, Jaiswal A, Agarwal V, Bhadauria D, et al
. Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: A prospective study. Indian J Nephrol 2018;8:46-52.
Bagga A, Afzal K, Agarwal I, Agarwal V, Ali U, Bagai S, et al
. Management of steroid sensitive nephrotic syndrome: Revised guidelines. Indian Pediatr 2008;45:203–14.
Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al
. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020;35:1529-61.
Hamasaki Y, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, et al
. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol 2013;28:765–71.
Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al
. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 2006;21:344-9.
Indian Society of Pediatric Nephrology, Gulati A, Bagga A, Gulati S, Mehta KP, Vijayakumar M. Management of steroid resistant nephrotic syndrome. Indian Pediatr 2009;46:35-47.
Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al
. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 2012;82:1130-5.
Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Neph rol 1999;13:13–8.
Banaszak B, Banaszak P. The increasing incidence of initial steroid resistance in childhood nephrotic syndrome. Pediatr Nephrol 2012;27:927-32.
Inaba A, Hamasaki Y, Ishikura K, Hamada R, Sakai T, Hataya H. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children. Pediatr Nephrol 2016;31:425-34.
Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: A randomized controlled trial. Am J Kidney Dis 2009;53:760-9.
Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al
. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80:868-78.
Klaassen I, Özgören B, Sadowski CE, Möller K, van Husen M, Lehnhardt A, et al
. Response to cyclosporine in steroid-resistant nephrotic syndrome: Discontinuation is possible. Pediatr Nephrol 2015;30:1477-83.
Gulati S, Sengupta D, Sharma RK, Sharma A, Gupta RK, Singh U, et al
. Steroid resistant nephrotic syndrome: Role of histopathology. Indian Pediatr 2006;43:55-60.
Büscher AK, Beck BB, Melk A, Hoefele J, Kranz B, Bamborschke D, et al
. Rapid response to Cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2016;11:245–53.
Sinha A, Sharma A, Mehta A, Gupta R, Gulati A, Hari P, et al
. Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome. Indian J Nephrol 2013;23:41-6.
] [Full text]
Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, et al
. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-A randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatr Nephrol 2008;23:1483-93.
Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol 2000;15:74-8.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]